Table 2.
Select list of studies for non-clear cell renal cell cancer (non-ccRCC) histologies.
| Study | Study Type | Histology | Treatment | Outcomes |
|---|---|---|---|---|
| Choueiri et al [31] |
Retrospective analysis |
PRCC | Sunitinib vs. Sorafenib | PFS of 11.9 vs. 5.1 months (p < 0.001) |
| Dutcher et al. [32] | Retrospective analysis |
Non-ccRCC | Temsirolimus vs. IFN-a | OS of 11.6 vs. 4.3 months (HR 0.49; 95% CI 0.29–0.85) |
| KEYNOTE 426 [33] | Prospective, randomized phase III (sub-group analysis) |
RCC with sarcomatoid differentiation | Pembrolizumab + Axitinib vs. Sunitinib | PFS not reached vs. 8.4 months (HR 0.54; 95% CI 0.29–1.00) |
| McKay et al. [34] | Retrospective analysis |
Non-ccRCC | Monotherapy or combination PD-1/PD-L1 inhibitor | ORR 28% for PRCC 33% for translocation 43% for sarcomatoid/rhabdoid differentiation |
| KEYNOTE 427 [35] | Prospective, open-label phase II |
Non-ccRCC | Pembrolizumab | ORR 25.4% for PRCC 9.5% for ChRCC 34.6% for unclassified RCC |
| CheckMate 214 [36] | Prospective, randomized phase III (post-hoc analyses) |
RCC with sarcomatoid differentiation | Ipilimumab + Nivolumab vs. Sunitinib | ORR of 56.7% vs. 19.2% |
| Oudard et al. [37] | Prospective, open-label phase II |
CDCs | Cisplatin and Gemcitabine | ORR 26.0% OS of 11.0 months |
Abbreviations: CDCs, collecting duct carcinomas; ChRCC, chromophobe renal cell cancers; non-ccRCC, non-clear cell renal cell cancer; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PRCC, papillary renal cell cancer; RCC, renal cell cancer.